In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography

H. Barthel; H. Wilson; D. R. Collingridge; G. Brown; S. Osman; S. K. Luthra; F. Brady; P. Workman; P. M. Price; E. O. Aboagye

doi:10.1038/sj.bjc.6601862

In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography

H. Barthel, H. Wilson, D. R. Collingridge, G. Brown, S. Osman, S. K. Luthra, F. Brady, P. Workman, P. M. Price, E. O. Aboagye

Research output: Contribution to journal › Article › peer-review

Abstract

Development of hypoxia-targeted therapies has stimulated the search for clinically applicable noninvasive markers of tumour hypoxia. Here, we describe the validation of [18F]fluoroetanidazole ([18F]FETA) as a tumour hypoxia marker by positron emission tomography (PET). Cellular transport and retention of [18F]FETA were determined in vitro under air vs nitrogen. Biodistribution and metabolism of the radiotracer were determined in mice bearing MCF-7, RIF-1, EMT6, HT1080/26.6, and HT1080/1-3C xenografts. Dynamic PET imaging was performed on a dedicated small animal scanner. [ 18F]FETA, with an octanol-water partition coefficient of 0.16 ± 0.01, was selectively retained by RIF-1 cells under hypoxia compared to air (3.4- to 4.3-fold at 60-120 min). The radiotracer was stable in the plasma and distributed well to all the tissues studied. The 60-min tumour/muscle ratios positively correlated with the percentage of pO2 values

Original language	English
Pages (from-to)	2232-2242
Number of pages	10
Journal	British Journal of Cancer
Volume	90
Issue number	11
DOIs	https://doi.org/10.1038/sj.bjc.6601862
Publication status	Published - 1 Jun 2004

Keywords

2-nitroimidazole
[18F]FETA
Imaging
PET
Tumour hypoxia

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.bjc.6601862

Cite this

@article{636eb4daa147444eaa88a2aac674094c,

title = "In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography",

abstract = "Development of hypoxia-targeted therapies has stimulated the search for clinically applicable noninvasive markers of tumour hypoxia. Here, we describe the validation of [18F]fluoroetanidazole ([18F]FETA) as a tumour hypoxia marker by positron emission tomography (PET). Cellular transport and retention of [18F]FETA were determined in vitro under air vs nitrogen. Biodistribution and metabolism of the radiotracer were determined in mice bearing MCF-7, RIF-1, EMT6, HT1080/26.6, and HT1080/1-3C xenografts. Dynamic PET imaging was performed on a dedicated small animal scanner. [ 18F]FETA, with an octanol-water partition coefficient of 0.16 ± 0.01, was selectively retained by RIF-1 cells under hypoxia compared to air (3.4- to 4.3-fold at 60-120 min). The radiotracer was stable in the plasma and distributed well to all the tissues studied. The 60-min tumour/muscle ratios positively correlated with the percentage of pO2 values",

keywords = "2-nitroimidazole, [18F]FETA, Imaging, PET, Tumour hypoxia",

author = "H. Barthel and H. Wilson and Collingridge, {D. R.} and G. Brown and S. Osman and Luthra, {S. K.} and F. Brady and P. Workman and Price, {P. M.} and Aboagye, {E. O.}",

year = "2004",

month = jun,

day = "1",

doi = "10.1038/sj.bjc.6601862",

language = "English",

volume = "90",

pages = "2232--2242",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "11",

}

TY - JOUR

T1 - In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography

AU - Barthel, H.

AU - Wilson, H.

AU - Collingridge, D. R.

AU - Brown, G.

AU - Osman, S.

AU - Luthra, S. K.

AU - Brady, F.

AU - Workman, P.

AU - Price, P. M.

AU - Aboagye, E. O.

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Development of hypoxia-targeted therapies has stimulated the search for clinically applicable noninvasive markers of tumour hypoxia. Here, we describe the validation of [18F]fluoroetanidazole ([18F]FETA) as a tumour hypoxia marker by positron emission tomography (PET). Cellular transport and retention of [18F]FETA were determined in vitro under air vs nitrogen. Biodistribution and metabolism of the radiotracer were determined in mice bearing MCF-7, RIF-1, EMT6, HT1080/26.6, and HT1080/1-3C xenografts. Dynamic PET imaging was performed on a dedicated small animal scanner. [ 18F]FETA, with an octanol-water partition coefficient of 0.16 ± 0.01, was selectively retained by RIF-1 cells under hypoxia compared to air (3.4- to 4.3-fold at 60-120 min). The radiotracer was stable in the plasma and distributed well to all the tissues studied. The 60-min tumour/muscle ratios positively correlated with the percentage of pO2 values

AB - Development of hypoxia-targeted therapies has stimulated the search for clinically applicable noninvasive markers of tumour hypoxia. Here, we describe the validation of [18F]fluoroetanidazole ([18F]FETA) as a tumour hypoxia marker by positron emission tomography (PET). Cellular transport and retention of [18F]FETA were determined in vitro under air vs nitrogen. Biodistribution and metabolism of the radiotracer were determined in mice bearing MCF-7, RIF-1, EMT6, HT1080/26.6, and HT1080/1-3C xenografts. Dynamic PET imaging was performed on a dedicated small animal scanner. [ 18F]FETA, with an octanol-water partition coefficient of 0.16 ± 0.01, was selectively retained by RIF-1 cells under hypoxia compared to air (3.4- to 4.3-fold at 60-120 min). The radiotracer was stable in the plasma and distributed well to all the tissues studied. The 60-min tumour/muscle ratios positively correlated with the percentage of pO2 values

KW - 2-nitroimidazole

KW - [18F]FETA

KW - Imaging

KW - PET

KW - Tumour hypoxia

U2 - 10.1038/sj.bjc.6601862

DO - 10.1038/sj.bjc.6601862

M3 - Article

SN - 0007-0920

VL - 90

SP - 2232

EP - 2242

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 11

ER -

In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this